Home
    Disclaimer
    Heroin molecular structure

    Heroin Stats & Data

    H Boy Junk Dope Gear diamorphine
    NPS DataHub
    MW369.42
    FormulaC21H23NO5
    CAS561-27-3
    IUPAC(9-acetyloxy-3-methyl-2,4,4~{a},7,7~{a},13-hexahydro-1~{H}-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl) acetate
    SMILESCC(=O)OC1C=CC2C3N(C)CCC22C1Oc1c(OC(C)=O)ccc(C3)c12
    InChIKeyGVGLGOZIDCSQPN-PVHGPHFFSA-N
    Opioids
    Chemical Class Opioid
    Psychoactive Class Depressant
    Half-Life Diamorphine (heroin) ~3 minutes (plasma); primary active metabolite morphine ~2–3 hours. 6‑MAM is short‑lived and contributes to early effects.

    Pharmacology

    DrugBank
    State Solid

    Description

    Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom.

    Mechanism of Action

    When administered orally, diamorphine experiences extensive first-pass metabolism by way of deacetylation to generate the active metabolites 6-monoacetylmorphine (6-MAM) and morphine . Alternatively, when given as an injection the acetyl groups present in the diamorphine/diacetylmorphine compound confer the substance lipophilicity that facilitates diamorphine's rapid crossing of the blood-brain-barrier . Once in the brain, diamorphine is metabolised via deacetylation to the active 6-MAM and morphine metabolites as well . Despite diamorphine possessing little to no opioid agonist activity itself, its rapid transit across the blood-brain-barrier elicits a far faster onset of activity in comparison to the extensive first-pass metabolism of oral administration . Regardless, the metabolism of diamorphine to morphine makes heroin a prodrug for the delivery of morphine . Morphine is subsequently a mu-opioid agonist. It acts on endogenous mu-opioid receptors that are spread in discrete packets throughout the brain, spinal cord and gut in almost all mammals . Morphine, along with other opioids, are agonists to four endogenous neurotransmitters . They are beta-endorphin, dynorphin, leu-enkephalin, and met-enkephalin . The body responds to morphine in the brain by reducing (and sometimes stopping) production of the endogenous opioids when morphine is present .

    Pharmacodynamics

    The onset of heroin's effects is dependent on the method of administration. Taken orally, heroin is totally metabolized in vivo via extensive first-pass metabolism into morphine before crossing the blood-brain barrier; so the effects are the same as orally administered morphine . Take by injection, diamorphine's acetyl groups facilitate rapid crossing into the brain . Once in the brain, heroin is rapidly metabolized into morphine by removal of the acetyl groups, therefore making it a prodrug for the delivery of morphine . Subsequently, whether eliciting actions peripherally (on smooth muscle, skeletal muscle, kidney, lung, liver, or spleen tissue , for example) or on the central nervous system, it is ultimately the morphine metabolite of heroin that then binds with opioid receptors and produces the narcotic opioid effects commonly associated with the substance .

    Metabolism

    Once administered into the body, diamorphine undergoes deacetylation via various esterase enzymes to generate active metabolites like 6-monoacetylmorphine and morphine . In particular, when administered orally, diamorphine undergoes extensive first pass metabolism .

    Absorption

    Bioavailability is less than 35% when orally administered . In particular, some studies have determined that the bioavailability of orally administered diamorphine could be as low as 22.9% (16.4-29.4%) on average in opioid-naive subjects . Nevertheless, diamorphine administered by any many medically indicated routes of administration leads to a rapid absorption . Peak serum levels are achieved five to ten minutes subcutaneously, three to five minutes intranasally and intramuscularly, and less than one minute intravenously .

    Toxicity

    Overdosage with diamorphine well characterised by a number of symptoms including respiratory depression, pulmonary oedema, muscle flaccidity, coma or stupor, constricted pupils, cold, clammy skin and occasionally bradycardia and hypotension . The antidote for heroin overdose or poisoning is naloxone .

    Indication

    Diamorphine, as a prescription medication in the United Kingdom, is indicated for use in the treatment of severe pain associated with surgical procedures, myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary edema .

    Half-life

    In humans, administered diamorphine has a half-life of approximately two to three minutes .

    Protein Binding

    Diamorphine does not bind to plasma protein . However, considering diamorphine is considered a prodrug for morphine, morphine itself is about 20 to 35% reversibly bound to human plasma proteins .

    Elimination

    The majority of the drug is excreted via the kidney as glucuronides and to a much lesser extent as morphine . About 7-10 % is eliminated via the biliary system into the faeces .

    Volume of Distribution

    Data regarding the volume of distribution specific to diamorphine is not readily accessible or available. However, considering diamorphine is considered a prodrug for morphine, the volume of distribution of morphine has been determined to be approximately 1 to 6 L/kg .

    Clearance

    Some studies have determined a relatively high systemic diacetylmorphine clearance of about 8.7 +/- 2.6 L/min, suggesting that the intestine, liver, and blood might all collectively take part in the first pass metabolism of diacetylmorphine to morphine , although such clearance observations were made only in opioid-addicted individuals . However, considering diamorphine is considered a prodrug for morphine, the mean adult plasma clearance of morphine is approximately 20 to 30 mL/min/kg .

    Receptor Profile

    Receptor Actions

    Agonists
    μ-opioid receptor agonist (full)
    Other
    prodrug of 6-monoacetylmorphine
    prodrug of morphine

    Receptor Binding

    Mu-type opioid receptor agonist
    Kappa-type opioid receptor agonist
    Delta-type opioid receptor agonist

    History & Culture

    1874–1897

    Diamorphine was first synthesized in 1874 by C.R. Alder Wright, an English chemist working at St. Mary's Hospital Medical School in London. Wright had been experimenting with combining morphine with various acids, achieving the synthesis by boiling anhydrous morphine alkaloid with acetic anhydride. However, Wright's invention did not lead to any immediate developments. The compound remained obscure until it was independently re-synthesized 23 years later by chemist Felix Hoffmann at the Bayer pharmaceutical company in Elberfeld, Germany. Hoffmann's supervisor Heinrich Dreser had instructed him to acetylate morphine with the objective of producing codeine, a constituent of the opium poppy that is less potent and less addictive than morphine. Instead, the experiment produced an acetylated form of morphine approximately one and a half to two times more potent than morphine itself. Hoffmann synthesized the compound on 21 August 1897, just eleven days after he had synthesized aspirin using a similar acetylation process.

    1898–1924

    Bayer began marketing diacetylmorphine as an over-the-counter medication under the trademark name "Heroin" in 1898, a name reputedly coined by the head of Bayer's research department based on the German word "heroisch" meaning "heroic" or "strong." The company developed it primarily as a morphine substitute for cough suppressants that purportedly lacked morphine's addictive properties. Since morphine was a popular recreational drug at the time, Bayer sought to market a similar but non-addictive alternative. From 1898 through 1910, diamorphine was actively marketed as a non-addictive cough suppressant and morphine substitute. The 11th edition of the Encyclopædia Britannica, published in 1910, recommended heroin as preferable to morphine for treating the cough associated with pulmonary tuberculosis. However, contrary to Bayer's advertising claims, heroin would soon demonstrate one of the highest addiction rates among its users. Bayer ultimately lost its trademark rights to heroin, along with aspirin, under the 1919 Treaty of Versailles following Germany's defeat in World War I.

    1914–1930

    The United States passed the Harrison Narcotics Tax Act in 1914 to regulate the sale and distribution of diacetylmorphine and other opioids, initially allowing the drug to be prescribed and sold for medical purposes. A decade later, in 1924, the United States Congress passed the Heroin Act, banning its sale, importation, and manufacture entirely. Internationally, the Health Committee of the League of Nations banned diacetylmorphine in 1925, though implementation took more than three years. During this interim period, clandestine chemists produced massive quantities of the first designer drugs, including various diesters and monoesters of morphine and acetylated analogues of related compounds like hydromorphone and dihydromorphine, to meet continued worldwide demand. This production continued until 1930, when the Committee enacted the first major legislation banning diacetylmorphine analogues that offered no therapeutic advantage over existing medications.

    1930–present

    The French Connection trafficking route emerged in the 1930s, establishing one of the first major international heroin distribution networks. During World War II, heroin trafficking to the United States was virtually eliminated due to temporary trade disruptions caused by the conflict. Following the war, organized crime groups exploited the weakness of the postwar Italian government and established heroin laboratories in Sicily, strategically located along historic opium trade routes into Europe and the United States. Large-scale heroin production in China effectively ended with the communist victory in the civil war during the late 1940s. However, in the late 1960s and early 1970s, support for anti-communist Chinese Nationalist forces near the Sino-Burmese border and Hmong tribesmen in Laos contributed to the development of the Golden Triangle opium production region. Following the American withdrawal from Vietnam in 1973, this region supplied approximately one-third of the heroin consumed in the United States. The Balkan route has since become the principal corridor for trafficking illegal opiates, primarily heroin, from Afghanistan to Western and Central Europe.

    Heroin use became particularly prevalent among jazz musicians during the mid-twentieth century. Notable figures affected included vocalist Billie Holiday, saxophonists Charlie Parker and Art Pepper, trumpeter and vocalist Chet Baker, guitarist Joe Pass, and pianist and singer Ray Charles—what observers described as a "staggering number" of jazz musicians who became addicted. The substance similarly affected rock musicians from the late 1960s through the 1990s. Prominent cases included Nirvana vocalist Kurt Cobain, whose addiction was extensively documented, and Pantera frontman Phil Anselmo, who turned to heroin while touring to manage chronic back pain. Other notable musicians who used heroin included James Taylor, Jimmy Page, John Lennon, Eric Clapton, Johnny Winter, Keith Richards, Janis Joplin, and many others. The drug's influence on these communities led numerous musicians to reference their heroin use in their work. Anthropologist Michael Agar once characterized heroin as "the perfect whatever drug," encapsulating its appeal across diverse contexts.

    Subjective Effect Notes

    physical: The physical effects of heroin can be broken down into several components which progressively intensify proportional to dosage.

    cognitive: The cognitive effects of heroin can be broken down into several components which progressively intensify proportional to dosage.

    Effect Profile

    Curated + 470 Reports
    Opioid 8.6

    Strong euphoria, pain relief, and sedation with moderate itching/nausea

    Euphoria / Warmth×3
    107.4 13/20
    Analgesia×2
    91.9 0/20
    Sedation / Relaxation×1
    94.1 7/20
    Itching / Nausea×1
    77.0 3/20
    Catalog Erowid

    User Experiences

    Euphoria "It's a rush that's I've never experienced before in my life (unless I was on hallucinogens and thought I was in danger or something)." Bluelight
    Sedation "It didn't last very long until I began nodding off, and had a similar experience to falling asleep, but the hypnogogic imagery was compleatly different than that of a normal night." Bluelight
    Itching/nausea "I was on sick leave." Bluelight

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Diamorphine (heroin) ~3 minutes (plasma); primary active metabolite morphine ~2–3 hours. 6‑MAM is short‑lived and contributes to early effects.
    Addiction Potential
    Very high. Heroin is highly addictive, with rapid development of tolerance and physical dependence. Withdrawal can be severe.

    Tolerance Decay

    Full tolerance 7d Half tolerance 3d Baseline ~7d

    Clinical and community data indicate rapid tolerance accrual with daily use and partial decay within days of cessation; overdose risk is highest after breaks when prior doses are resumed. Values are approximate and vary by individual, dose, and duration of use. Data quality mixed (clinical inference and user reports).

    Cross-Tolerances

    Other μ‑opioid agonists (e.g., morphine, oxycodone, hydromorphone)
    100% ●●○

    Experience Report Analysis

    Erowid BlueLight
    377 Reports
    1990–2021 Date Range
    153 With Age Data
    30 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 427 experience reports (377 Erowid + 93 Bluelight)

    427 Reports
    131 Effects Detected
    59 Positive
    53 Adverse
    19 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 59

    Euphoria 46.8% 91%
    Empathy 40.6% 82%
    Anxiety Suppression 33.7% 79%
    Sedation 32.1% 88%
    Contentment 32.0% 86%
    Stimulation 20.1% 82%
    Tactile Enhancement 19.9% 88%
    Body High 15.5% 89%
    Music Enhancement 14.0% 90%
    Vivid Dreams 14.0% 82%
    Drowsiness 14.0% 86%
    Tingling 12.0% 78%
    Thought Deceleration 12.0% 78%
    Heaviness 12.0% 87%
    Numbness 12.0% 90%
    Warmth 10.0% 90%
    Sociability Enhancement 10.0% 82%
    Focus Enhancement 9.0% 70%
    Thought Acceleration 8.0% 79%
    Joy 8.0% 85%

    Adverse Effects 53

    Nausea 31.1% 82%
    Confusion 19.7% 85%
    Body Load 18.0% 83%
    Vomiting 18.0% 89%
    Ataxia 14.0% 78%
    Dizziness 10.0% 83%
    Dysphoria 10.0% 87%
    Fear 10.0% 81%
    Sweating 8.9% 91%
    Focus Suppression 8.0% 81%
    Insomnia 6.0% 82%
    Paranoia 6.0% 75%
    Sadness 6.0% 77%
    Double Vision 6.0% 83%
    Tremor 6.0% 85%
    Memory Suppression 5.6% 80%
    Headache 4.9% 80%
    Motor Impairment 4.6% 85%
    Pupil Dilation 4.5% 70%
    Increased Heart Rate 4.2% 70%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Heavy (n=24)
    Euphoria 54.2%
    Empathy 41.7%
    Anxiety Suppression 29.2%
    Tactile Enhancement 29.2%
    Confusion 29.2%
    Nausea 25.0%
    Hospital 25.0%
    Ego Dissolution 20.8%
    Focus Enhancement 20.8%
    Stimulation 20.8%
    Sedation 16.7%
    Sweating 12.5%
    Increased Heart Rate 12.5%
    Color Enhancement 12.5%
    Body High 12.5%

    Subjective Effect Ontology

    Experience Reports

    Structured effect tags extracted from 470 Erowid & Bluelight experience reports using a controlled vocabulary of 220+ canonical effects across 15 domains.

    Emotional

    euphoria 200 49.8% empathy 173 37.2% anxiety suppression 144 32.3%

    Gastrointestinal

    nausea 133 31.0%

    Motor

    sedation 137 36.7%

    5 unique effects extracted · Derived from Erowid & Bluelight reports

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 377 experience reports.

    Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.

    Intravenous dose range: 75.0–400.0 mg (median 200.0 mg)
    Effect Heavy (n=24)
    euphoria
    54%
    empathy
    42%
    anxiety suppression
    29%
    tactile enhancement
    29%
    confusion
    29%
    nausea
    25%
    hospital
    25%
    ego dissolution
    21%
    focus enhancement
    21%
    stimulation
    21%
    sedation
    17%
    sweating
    12%
    increased heart rate
    12%
    color enhancement
    12%
    body high
    12%
    auditory effects
    12%
    muscle tension
    8%
    pupil dilation
    8%
    motor impairment
    8%

    Dosage Distribution

    Dose distribution from experience reports

    Insufflated

    Median: 60.0 mg IQR: 30.0–100.0 mg n=10

    Intravenous

    Median: 200.0 mg IQR: 75.0–400.0 mg n=22

    Real-World Dose Distribution

    62K Doses

    From 243 individual dose entries

    Rectal (n=32)

    Median: 40.0mg 25th: 30.0mg 75th: 80.0mg 90th: 80.0mg

    Insufflated (n=27)

    Median: 16.0mg 25th: 7.5mg 75th: 35.0mg 90th: 79.6mg
    mg/kg median: 0.365 mg/kg 75th: 1.169

    Smoked (n=17)

    Median: 100.0mg 25th: 15.0mg 75th: 500.0mg 90th: 700.0mg
    mg/kg median: 4.673 mg/kg 75th: 6.692

    Oral (n=5)

    Median: 70.0mg 25th: 70.0mg 75th: 70.0mg 90th: 70.0mg

    Intravenous (n=45)

    Median: 125.0mg 25th: 50.0mg 75th: 250.0mg 90th: 500.0mg
    mg/kg median: 2.709 mg/kg 75th: 4.443

    Intramuscular (n=6)

    Median: 130.0mg 25th: 7.75mg 75th: 812.5mg 90th: 2200.0mg
    mg/kg median: 1.637 mg/kg 75th: 9.973

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Insufflated

    Median: 0.826 mg/kg IQR: 0.378–1.264 mg/kg n=10

    Intravenous

    Median: 3.15 mg/kg IQR: 1.297–5.51 mg/kg n=22

    Smoked

    Median: 5.263 mg/kg IQR: 3.799–6.297 mg/kg n=9

    Redose Patterns

    Redosing behavior across 237 reports

    15.2% Redosed
    1.2 Avg Doses
    60m Median Interval

    Opioid Equivalence (MME)

    NIH HEAL 2024 & CDC 2022
    ⚠ Citation & Disclaimer: Conversion factors sourced from the NIH HEAL Initiative MME Calculator (Adams et al., PAIN 2025), the CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, and the MDCalc MME Calculator. These are approximate equianalgesic ratios for educational reference only. Individual responses vary significantly based on genetics, tolerance, cross-tolerance, and route of administration. This is not medical advice. Do not use these conversions to adjust opioid dosing without professional medical guidance.
    6.7 mg Heroin 10 mg Morphine (oral)
    MME factor 1.5×

    Heroin (diacetylmorphine) ~6.7 mg ≈ 10 mg Morphine oral

    Illicit substance; purity varies widely. This conversion is approximate.

    Legal Status

    Single Convention on Narcotic Drugs 1961 (Schedules I and IV)
    Country Status Notes
    Australia Schedule I (Narcotic Drugs Act) Listed in Schedule I of the Narcotic Drugs Act of 1967. Personal quantities under 1 gram have been decriminalized in the Australian Capital Territory as of 28 October 2023.
    Austria Illegal (SMG) Illegal to possess, produce, and sell under the Suchtmittelgesetz (SMG), Austria's Narcotic Substances Act.
    Brazil Controlled substance Listed as a controlled substance under national drug legislation. Production, distribution, and possession are prohibited.
    Canada Schedule I (CDSA) Controlled under the Controlled Drugs and Substances Act. Since September 2016, Health Canada has permitted prescription of pharmaceutical diacetylmorphine to severe addicts as a treatment regimen. A 2011 Supreme Court decision established a constitutional right under Section 7 of the Charter of Rights and Freedoms to access supervised injection sites.
    Czech Republic Decriminalized (personal use) Personal possession of 1.5g or less has been decriminalized, with penalties comparable to a parking fine. Sales, production, and possession of larger quantities remain criminal offenses.
    Finland Controlled substance Classified as a controlled substance under Finnish law. Production, distribution, and possession are illegal without a license.
    Germany Anlage I, II, III BtMG Controlled under the Betäubungsmittelgesetz (Narcotics Act). Manufacturing, importing, possessing, selling, or transferring without license is prohibited. An exception exists for approved addiction treatment preparations, which may be prescribed on a narcotic prescription form. Since May 2009, heroin can be prescribed to addicts over 23 years old who have been addicted for at least 5 years and have attempted two other therapies.
    Italy Tabella I Listed in Tabella I of the 'Tabelle delle sostanze stupefacenti e psicotrope.' Possession, purchase, and sale are illegal.
    Latvia Schedule I Classified as a Schedule I controlled substance under Latvian drug legislation. Possession, production, and distribution are prohibited.
    New Zealand Class A Controlled as a Class A substance under the Misuse of Drugs Act, the most restrictive classification carrying the most severe penalties.
    Norway Schedule I Illegal to buy or possess without a special license. The government has established needle exchange facilities where addicts can obtain clean injection equipment, though the substance itself remains prohibited.
    Poland Controlled substance Illegal to produce, sell, and possess under the 'wykaz środków odurzających i substancji psychotropowych' (list of narcotic drugs and psychotropic substances).
    Portugal Decriminalized (personal use) Personal use decriminalized by Law 30/2000, effective July 2001. Possession of less than 1g is not a criminal offense, though the substance may be seized and the individual referred to a dissuasion commission for potential treatment. Sale or possession above the personal threshold remains a criminal offense punishable by imprisonment.
    Russia Schedule I Classified as a Schedule I controlled substance under Russian narcotic drug legislation. Possession, production, and distribution are prohibited.
    Switzerland Controlled (Verzeichnis D) Specifically named under Verzeichnis D of the Betäubungsmittelgesetz. Generally illegal to possess, but legally available to registered addicts through state-sanctioned heroin-assisted treatment programs.
    United Kingdom Schedule II / Class A Controlled under the Misuse of Drugs Act. Illegal to buy, sell, or possess without a license. However, under the name diamorphine, it remains a legal prescription medication indicated for severe pain associated with surgical procedures, myocardial infarction, pain in terminally ill patients, and relief of dyspnoea in acute pulmonary edema.
    United States Schedule I Controlled under the Controlled Substances Act as an opium derivative. Manufacturing, buying, possessing, or distributing without a DEA license is illegal. Heroin was federally prohibited in 1924 through the Heroin Act.

    Harm Reduction

    drugs.wiki

    - Street heroin varies widely in purity and is frequently adulterated. Laboratory drug checking has repeatedly found heroin samples containing fentanyl, fluorofentanyl, 4‑ANPP precursors, caffeine/lidocaine cuts, and xylazine; these substantially increase overdose and morbidity risks. Always treat unknown powder as potentially fentanyl‑positive and use fentanyl test strips when feasible. Note that fentanyl strips do not detect nitazenes.

    - Xylazine (a veterinary sedative) may be present with heroin/fentanyl (“tranq”). Naloxone should still be given during overdose because it reverses the opioid component, but it does not reverse xylazine’s sedative effects; expect prolonged sedation and provide rescue breathing.

    - Do not mix with other depressants (alcohol, benzodiazepines, GHB, barbiturates, Z‑drugs). This combination is a leading pattern in fatal opioid poisonings due to additive respiratory depression.

    - Gabapentinoids (pregabalin/gabapentin) significantly elevate overdose risk, especially with opioids; multiple EU countries report rising fatalities with pregabalin involvement. Avoid this combination.

    - Tolerance drops quickly after even short breaks; resuming a previous dose after abstinence is a common cause of fatal overdose. Start far lower after any lapse.

    - If injecting, base heroin (No.3) must be acidified with citric or ascorbic acid to dissolve; always use sterile water, new equipment, and avoid sharing to prevent infections (HIV, HBV/HCV, SSTIs). Rotate sites and use the finest appropriate needle and filtration possible.

    - Smoked/insufflated routes generally have a slower onset and slightly lower overdose risk than IV; however, polydrug use still drives most severe outcomes. Use with a trusted person present and have naloxone on hand.

    - Naloxone saves lives: carry it, train peers, and expect that multiple doses may be required if fentanyl/nitazenes are involved. Take‑home naloxone (THN) programmes are expanding across Europe; pharmacy access is widespread in the US. Continue rescue breathing while awaiting EMS.

    - EUDA notes diamorphine crosses the BBB within ~20 s after injection and has a plasma half‑life of ~3 minutes; much of the clinical effect comes from rapid formation of 6‑MAM and morphine. Oral ingestion is comparatively ineffective. These kinetics explain rapid onset (“rush”), short parent half‑life, and multi‑hour effects.

    - Terminology warning: “China white” is now often used for non‑heroin synthetic opioids (e.g., fentanyl analogues). Never assume composition from street names; rely on testing and conservative dosing.

    ← Back to Heroin